Company intelligence / Profile preview

Taij Group

Taipei, Taipei City, Taiwanfacebook.com ↗

Ownership: Private
Employees: ~70
Development stage: Other

Overview

TaiGen has developed several novel therapeutics targeting infectious diseases and complications from diabetes. Its lead product, Nemonoxacin (Taigexyn®), has been approved in multiple countries for community-acquired pneumonia. Other candidates include TG‑1000 for influenza and Furaprevir + Imitasvir combination therapy for hepatitis C. Burixafor targets stem cell mobilization.

Therapeutic areas: HematologyInfectious Diseases
Modalities: Small moleculePeptidesStem cell mobilizerAntiviral agents
Industry: Biotech

Partnerships

Out-license agreements with P&G Pharmaceuticals and others covering >30 countries worldwide for Taigexyn®alliances with global pharma companies

Beyond the preview

Go deeper on Taij Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taij Group.

Explore the full profile